FDA: anti-counterfeiting successes are 'drop in the bucket'; Pfizer sells PR plant to Mexico's Neolpharma;

> The FDA says its anti-counterfeiting successes are just "a drop in the bucket." Report

> Mylan ($MYL) is buying an oncology drug production plant in India for $32.5 million. Article

> Pfizer ($PFE) has sold one of the Puerto Rico plants it earmarked for closure to Mexican drugmaker Neolpharma. Article

> Biostar Pharmaceuticals has inked a $3 million deal to manufacture drugs for a Chinese hospital. Article

> The cost of many medicines in Ireland are to drop 10% after the government struck a deal with manufacturers. Article

> Tris Pharma has leased a New Jersey warehouse to accommodate a spike in manufacturing activity. Article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.